loading
Allogene Therapeutics Inc stock is traded at $1.82, with a volume of 1.99M. It is down -6.15% in the last 24 hours and up +9.58% over the past month. Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.95
Open:
$1.85
24h Volume:
1.99M
Relative Volume:
0.40
Market Cap:
$399.43M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.8585
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-14.49%
1M Performance:
+9.58%
6M Performance:
-27.09%
1Y Performance:
-62.96%
1-Day Range:
Value
$1.8107
$1.94
1-Week Range:
Value
$1.80
$2.145
52-Week Range:
Value
$1.32
$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
Name
Allogene Therapeutics Inc
Name
Phone
(650) 457-2700
Name
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Employee
361
Name
Twitter
@AllogeneTx
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
ALLO's Discussions on Twitter

Compare ALLO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.815 399.43M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
688.19 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
633.30 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.25 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.59 27.34B 3.30B -501.07M 1.03B -2.1146

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-08-24 Resumed Oppenheimer Outperform
May-31-24 Initiated Piper Sandler Overweight
Jan-05-24 Downgrade Guggenheim Buy → Neutral
Jan-05-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-08-23 Initiated Citigroup Buy
Jun-26-23 Resumed Oppenheimer Outperform
Mar-21-23 Initiated Bernstein Mkt Perform
Jan-24-23 Upgrade JP Morgan Neutral → Overweight
Jan-06-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-12-22 Downgrade BofA Securities Buy → Underperform
Aug-10-22 Downgrade Raymond James Outperform → Mkt Perform
Jul-15-22 Upgrade Goldman Neutral → Buy
Jun-03-22 Initiated Robert W. Baird Neutral
Feb-28-22 Reiterated B. Riley Securities Buy
Oct-20-21 Initiated Cowen Outperform
Oct-08-21 Downgrade Goldman Buy → Neutral
Oct-08-21 Downgrade Stifel Buy → Hold
Sep-23-21 Upgrade Raymond James Mkt Perform → Outperform
Jun-21-21 Resumed Jefferies Buy
May-20-21 Upgrade Truist Hold → Buy
May-14-21 Initiated B. Riley Securities Buy
Jan-26-21 Upgrade Stifel Hold → Buy
Dec-10-20 Resumed H.C. Wainwright Buy
Nov-24-20 Initiated BofA Securities Buy
Oct-23-20 Initiated RBC Capital Mkts Outperform
Jun-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-29-20 Reiterated H.C. Wainwright Buy
May-19-20 Upgrade ROTH Capital Neutral → Buy
May-15-20 Upgrade Guggenheim Neutral → Buy
May-14-20 Reiterated H.C. Wainwright Buy
May-14-20 Downgrade SunTrust Buy → Hold
Apr-13-20 Initiated SunTrust Buy
Mar-13-20 Initiated H.C. Wainwright Buy
Mar-05-20 Initiated Stifel Hold
Feb-24-20 Initiated Berenberg Hold
Dec-18-19 Initiated JMP Securities Mkt Outperform
Nov-04-19 Initiated Canaccord Genuity Buy
Aug-09-19 Initiated BTIG Research Buy
Jun-05-19 Initiated ROTH Capital Neutral
May-31-19 Initiated Guggenheim Neutral
May-23-19 Initiated Stifel Hold
Mar-29-19 Initiated Piper Jaffray Overweight
View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

pulisher
08:48 AM

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times

08:48 AM
pulisher
08:48 AM

When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan

08:48 AM
pulisher
Feb 27, 2025

Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - PR Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

What Will Allogene Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight - The Malaysian Reserve

Feb 25, 2025
pulisher
Feb 25, 2025

Allogene Therapeutics Expands Strategic Collaboration with Foresight Diagnostics for MRD Assay Development in Large B-Cell Lymphoma Treatment - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Can Allogene's $37.3M Diagnostic Partnership Transform Lymphoma Treatment Outcomes? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model - Seeking Alpha

Feb 24, 2025
pulisher
Feb 23, 2025

Allogene Therapeutics (NASDAQ:ALLO) Sees Large Volume IncreaseWhat's Next? - MarketBeat

Feb 23, 2025
pulisher
Feb 23, 2025

Allogene stock plunges to 52-week low at $1.33 amid steep annual decline - MSN

Feb 23, 2025
pulisher
Feb 23, 2025

Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal year - MSN

Feb 23, 2025
pulisher
Feb 21, 2025

Insider Sell: Deborah Messemer Sells Shares of Allogene Therapeu - GuruFocus.com

Feb 21, 2025
pulisher
Feb 20, 2025

Allogene therapeutics director Deborah Messemer sells $32,350 in stock - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

Allogene Therapeutics Director Sells Shares Under Trading Plan - TradingView

Feb 20, 2025
pulisher
Feb 20, 2025

Allogene therapeutics director Deborah Messemer sells $32,350 in stock By Investing.com - Investing.com UK

Feb 20, 2025
pulisher
Feb 18, 2025

Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga

Feb 18, 2025
pulisher
Feb 18, 2025

Baird ‘encouraged’ by Allogene CAR-T therapy update - TipRanks

Feb 18, 2025
pulisher
Feb 17, 2025

Diffuse Large B-cell Lymphoma Market Expected to rise, 2034 | - openPR

Feb 17, 2025
pulisher
Feb 17, 2025

Allogene stock hits 52-week low at $1.76 amid market challenges - Investing.com Nigeria

Feb 17, 2025
pulisher
Feb 15, 2025

Allogene leaps on allogeneic CAR-T therapy success - The Pharma Letter

Feb 15, 2025
pulisher
Feb 14, 2025

Allogene reports promising results for CAR T therapy in lymphoma - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

abrdn plc Invests $776,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Allogene Therapeutics Announces Publication of Durable - GlobeNewswire

Feb 13, 2025
pulisher
Feb 13, 2025

Allogene reports promising results for CAR T therapy in lymphoma By Investing.com - Investing.com South Africa

Feb 13, 2025
pulisher
Feb 13, 2025

Allogene Therapeutics Announces Positive Phase 1 Results for Cema-Cel in Treating Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq

Feb 13, 2025
pulisher
Feb 12, 2025

Allogene stock plunges to 52-week low at $1.33 amid steep annual decline By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 11, 2025

A stock that deserves closer examination: Allogene Therapeutics Inc (ALLO) - US Post News

Feb 11, 2025
pulisher
Feb 10, 2025

Ratio Revelations: Allogene Therapeutics Inc (ALLO)’s Financial Metrics in the Spotlight - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Earl Martin Douglas Sells 6,404 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock - MarketBeat

Feb 10, 2025
pulisher
Feb 09, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Allogene Therapeutics Falls To US$1.51, But Insiders Sold At Lower Price - Simply Wall St

Feb 08, 2025
pulisher
Feb 06, 2025

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN

Feb 06, 2025
pulisher
Feb 05, 2025

Allogene Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 05, 2025
pulisher
Feb 05, 2025

Follicular Lymphoma Pipeline 2024: Comprehensive Clinical - openPR

Feb 05, 2025
pulisher
Feb 04, 2025

Allogene Therapeutics Announces Participation in February Investor Conferences - GlobeNewswire

Feb 04, 2025

Allogene Therapeutics Inc Stock (ALLO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.28
price down icon 4.34%
$23.06
price up icon 1.68%
$33.94
price up icon 1.01%
$19.96
price down icon 4.11%
biotechnology ONC
$245.22
price down icon 9.75%
$112.79
price down icon 0.24%
Cap:     |  Volume (24h):